EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review

Ziyu Zhang, Lankai Liao, Houfeng Zhou, Wen Xiang, Junyan Li

Frontiers in Immunology · 30.04.2026 · 17

DOI: 10.3389/fimmu.2026.1783590 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Immunology, online erschienen am 30.04.2026. Verfasst von Ziyu Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have been widely utilized in patients with cancer and established as a standard therapeutic modality for various solid tumors. Although generally well tolerated, ICIs can induce unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical oncology practice. Neurological immune-related adverse events (N-irAEs) are relatively rare, but the clinical management of high-grade N-irAEs is extremely challenging and potentially life-threatening. Concurrently, the nonspecific manifestations and extensive differential diagnoses of N-irAEs render their diagnosis highly difficult, which may result in suboptimal clinical management. Herein, we report on a case of a patient with advanced breast cancer who developed severe adverse reactions subsequent to treatment with pucotenlimab and was diagnosed with anti-aquaporin 4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) following multidisciplinary discussion. Despite prompt administration of high-dose methylprednisolone and plasma exchange therapy, the patient’s neurological symptoms progressively worsened, leading to multiple organ dysfunction syndrome and subsequent death. A literature review on N-irAEs is also presented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaBreast NeoplasmsAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsHumansFemaleAutoantibodiesAquaporin 4Fatal OutcomeMiddle Aged

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune-related adverse eventsmalignant tumor of breastneuromyelitis optica spectrum disorderpucotenlimab

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsAutoantibodiesAquaporin 4

Autor:innen und Institutionen

  • Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.
  • Department of Emergency Medicine, Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.
  • Department of Thyroid and Breast Surgery, Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.

Zitieren

APA

Zhang, Z., Liao, L., Zhou, H., Xiang, W., & Li, J. (2026). Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1783590

Vancouver

Zhang Z, Liao L, Zhou H, Xiang W, Li J. Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1783590

BibTeX
@article{Zhang2026,
  author = {Zhang, Ziyu and Liao, Lankai and Zhou, Houfeng and Xiang, Wen and Li, Junyan},
  title = {Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1783590}
}
Kostenlos starten →